肺癌常规人群中22C3检测PD-L1表达的患病率与异质性
在加拿大区域病理实验室8个月内对NSCLC活检和切除标本行22C3 PD-L1反射检测。1795例患者共2031次检测,可评估1713例中TPS<1%、1%-49%、≥50%分别占41.6%、28.6%、29.8%。活检与切除标本配对显示中度一致性,小活检面积<8 mm2时不一致率更高,转移灶活检可能提高高PD-L1表达检出比例。
要点
- NSCLC中PD-L1 TPS≥50%占29.8%,TPS<1%占41.6%。
- 活检与切除标本PD-L1一致性中等(κ=0.67),小活检易误判。
- 转移灶活检可能提高高PD-L1表达患者检出比例。
核心结论
- PD-L1瘤内异质性可导致相当比例PD-L1阴性小活检样本的状态误判。
- 转移部位活检可能增加高PD-L1表达患者的比例。
研究设计与样本
- 在加拿大区域参考病理实验室8个月期间,对NSCLC活检和切除标本反射性行22C3 IHC pharmDx检测。
- 共1795例患者完成2031次PD-L1检测,107例结果不确定(5.3%)。
- 可评估1713例,TPS低/高表达截断值分别为1%和50%。
主要发现
- 可评估1713例中TPS<1%占41.6%,TPS 1%-49%占28.6%,TPS≥50%占29.8%。
- EGFR野生型较突变型、鳞癌较腺癌、转移灶较原发灶的PD-L1表达率更高(均p<0.001)。
- 103例配对活检与切除标本PD-L1一致性中等(κ=0.67)。
- 48例活检TPS<1%中52%(25/48)切除标本TPS>1%;26例活检TPS≥50%中84.6%(22/26)切除标本一致。
- 活检总面积<8 mm2者与切除标本不一致率71.4%,≥8 mm2者为33.3%(p<0.026)。
关键数值与推荐
- TPS<1%定义为低表达以下,TPS≥50%定义为高表达。
- 活检总面积<8 mm2与≥8 mm2者不一致率分别为71.4%与33.3%(p<0.026)。
临床怎么用
- 小活检评估PD-L1阴性时需警惕瘤内异质性导致的误判。
- 对PD-L1阴性小活检可考虑转移灶再活检以更准确评估高表达。
局限性
- 单中心区域实验室8个月数据,结果外推需谨慎。
- 部分病例结果不确定或数据缺失(107例,5.3%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Programmed death-ligand 1 (PD-L1) is used as a biomarker for anti-programmed cell death protein-1 (PD-1) or anti-PD-L1 immunotherapies in NSCLC. We report here the results of population-based PD-L1 testing using the 22C3 IHC pharmDx Assay (Agilent Technologies) in a large Canadian regional reference pathology laboratory. METHODS: Testing was conducted reflexively on biopsies and resections for NSCLC during an 8-month period. Tumor proportion score (TPS) cutoffs for low and high expression were 1% and 50%, respectively. RESULTS: Altogether, 2031 PD-L1 tests were performed on specimens from 1795 patients, with 107 inconclusive results (5.3%). Excluding cases with inconclusive/missing data, proportions for the remaining 1713 patients were 41.6% for TPS less than 1%, 28.6% for TPS 1% to 49%, and 29.8% for TPS greater than or equal to 50%. Higher PD-L1 expression rates were noted in EGFR wild-type versus mutant tumors (p < 0.001), squamous versus adenocarcinoma (p < 0.001), and metastatic versus primary tumors (p < 0.001). PD-L1 among 103 patients with paired biopsy and resection specimens revealed moderate concordance (κ = 0.67). A total of 52% (25 of 48) of biopsies with TPS less than 1% had TPS greater than 1% in resection, whereas 84.6% (22 of 26) of biopsies with TPS greater than or equal to 50% were concordant in resected tumors. Discordance rates between biopsy and resection were 71.4% for biopsies with less than 8 mm2 total area, compared with 33.3% for biopsies with greater than or equal to 8 mm2 area (p < 0.026). Concordance among 27 patients with paired primary lung and metastatic tumor biopsies revealed only weak concordance (κ = 0.48). CONCLUSIONS: Intratumoral heterogeneity of PD-L1 expression may result in misclassification of PD-L1 status in a substantial proportion of PD-L1-negative small biopsy samples. Biopsy of metastatic site may increase proportion of patients with high PD-L1 expression.
引用
- Hwang DM, Albaqer T, Santiago RC, et al. Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer. J Thorac Oncol. 2021. PMID: 33915250. doi:10.1016/j.jtho.2021.03.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。